drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, genetically modified CAR T-cell therapy targeting GPRC5D. Patient T cells are engineered to express an anti-GPRC5D chimeric antigen receptor with CD3ζ and co-stimulatory signaling domains; CAR engagement activates T cells, inducing proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of GPRC5D-expressing malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an anti-GPRC5D chimeric antigen receptor with CD3ζ and co-stimulatory domains. Upon binding GPRC5D on malignant plasma cells, the CAR activates T-cell signaling, leading to expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of target cells.
drug_name
ICI201
nct_id_drug_ref
NCT05980507